Stock listing

Crispr Therapeutics Ag

Selected listing: A2AT0Z · LS · EUR · DE

Crispr Therapeutics Ag (Lang & Schwarz: A2AT0Z), Health Technology. Latest release Oct 2, 2026: CRISPR Therapeutics to Present Clinical Data on Zugocabtagene…

A2AT0Z:LSEURDEUpdated September 25, 2026

Ticker: Lang & Schwarz: A2AT0Z
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Crispr Therapeutics Ag

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

October 2, 2026

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

October 1, 2026

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

September 8, 2026

CRISPR Therapeutics Presents Phase 1a Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

August 31, 2026

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

August 28, 2026

All Crispr Therapeutics Ag news →

Research Crispr Therapeutics Ag

Crispr Therapeutics Ag company profile

View the public company page for Crispr Therapeutics Ag on 6ix.

Crispr Therapeutics Ag news

Read company news and market updates connected to Crispr Therapeutics Ag.

Crispr Therapeutics Ag investor events

Find investor webinars, events, and replay context for Crispr Therapeutics Ag.